Rhythm Pharmaceuticals (RYTM)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of Rhythm Pharmaceuticals (RYTM)
Rhythm Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in development and commercialization of therapies for patients with rare diseases. It is focused on the development and commercialization of peptide therapeutics for the treatment of gastrointestinal, or GI, diseases, and genetic deficiencies that result in metabolic disorders. The company's product candidate is setmelanotide (RM 493), which is a potent, melanocortin 4, or MC4, receptor agonist for the treatment of rare genetic disorders of obesity caused by MC4 pathway deficiencies. Geographically the company generates its revenue from the United states, Germany, and other with the majority being generated from the United states.
Key Insights
Critical company metrics and information
Share Price
$58.89Market Cap
$3.62 BillionTotal Outstanding Shares
61.46 Million SharesTotal Employees
226Dividend
No dividendIPO Date
October 5, 2017SIC Description
Pharmaceutical PreparationsHomepage
http://www.rhythmtx.com
Historical Stock Splits
Execution Date | Split Amount |
---|---|
No Historical Stock Splits |
Cash Flow Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Net Cash Flow From Financing Activities | $155.34 Million |
Net Cash Flow From Operating Activities | $-124.42 Million |
Net Cash Flow | $-15.77 Million |
Net Cash Flow From Investing Activities | $-46.69 Million |
Net Cash Flow, Continuing | $-15.77 Million |
Net Cash Flow From Investing Activities, Continuing | $-46.69 Million |
Net Cash Flow From Financing Activities, Continuing | $155.34 Million |
Net Cash Flow From Operating Activities, Continuing | $-124.42 Million |
Income Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
Operating Income/Loss | $-265.51 Million |
Research and Development | $226.68 Million |
Gross Profit | $99.72 Million |
Diluted Average Shares | $122.32 Million |
Cost Of Revenue | $12.81 Million |
Income Tax Expense/Benefit | $631000.00 |
Nonoperating Income/Loss | $7.20 Million |
Costs And Expenses | $378.05 Million |
Income/Loss From Continuing Operations After Tax | $-258.91 Million |
Net Income/Loss | $-258.91 Million |
Net Income/Loss Attributable To Parent | $-258.91 Million |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $1.33 Million |
Benefits Costs and Expenses | $370.81 Million |
Net Income/Loss Available To Common Stockholders, Basic | $-261.54 Million |
Basic Average Shares | $182.89 Million |
Revenues | $112.53 Million |
Selling, General, and Administrative Expenses | $138.55 Million |
Operating Expenses | $365.23 Million |
Preferred Stock Dividends And Other Adjustments | $1.33 Million |
Income/Loss From Continuing Operations Before Tax | $-258.28 Million |
Basic Earnings Per Share | $4.33 |
Diluted Earnings Per Share | $4.32 |
Balance Sheet
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Fixed Assets | $801000.00 |
Temporary Equity Attributable To Parent | $141.48 Million |
Liabilities And Equity | $363.57 Million |
Other Current Assets | $28.06 Million |
Inventory | $13.89 Million |
Noncurrent Assets | $23.23 Million |
Current Liabilities | $97.61 Million |
Cash | $298.39 Million |
Equity Attributable To Noncontrolling Interest | $0.00 |
Temporary Equity | $141.48 Million |
Liabilities | $210.88 Million |
Assets | $363.57 Million |
Equity | $11.21 Million |
Accounts Payable | $4.89 Million |
Other Current Liabilities | $92.72 Million |
Noncurrent Liabilities | $113.27 Million |
Current Assets | $340.34 Million |
Equity Attributable To Parent | $11.21 Million |
Other Non-current Assets | $22.43 Million |
Historical Dividends
Announcement Date | Payment Date | Record Date | Amount | Frequency |
---|---|---|---|---|
No historical dividends |
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
ⓒ 2024 Financhle. All Rights Reserved.